Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
52 hedge funds and large institutions have $8.72M invested in Navidea Biopharmaceuticals Inc. in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 4 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% less funds holding
Funds holding: 55 → 52 (-3)
14% less capital invested
Capital invested by funds: $10.1M → $8.72M (-$1.37M)
77% less call options, than puts
Call options by funds: $15K | Put options by funds: $66K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.78M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$144K |
| 3 |
SIM
Spark Investment Management
New York
|
+$42K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$38.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$267K |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$193K |
| 3 |
Millennium Management
New York
|
-$188K |
| 4 |
D.E. Shaw & Co
New York
|
-$154K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$60.3K |
NAVB Hedge Fund Activity: Q1 2017 in Review
52 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2017, worth a combined $8.72M — down 14% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NAVB positions and 4 closed out — a net gain of 1 holder — while 15 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $1.78M. The largest seller was Goldman Sachs, cutting an estimated $267K.
- 52 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2017, down from 55 in Q4 2016.
- Funds reported $8.72M of Navidea Biopharmaceuticals Inc. stock for Q1 2017, down 14% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2017 and 4 closed out, a net change of +1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2017 was BlackRock, an estimated $1.78M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2017 was Goldman Sachs, an estimated $267K sold.
Based on aggregated 13F filings for Q1 2017.